
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is fatal without treatment, but early detection and therapy can cure up to 70% of patients. The current best prognostic classification, the National Comprehensive Cancer Network International Prognostic Index, is insufficient to guide therapeutic decision-making for individual patients. No tumor-intrinsic prognostication...